Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
J Mol Diagn ; 23(1): 91-102, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33349347

RESUMEN

Carrier screening involves detection of carrier status for genes associated with recessive conditions. A negative carrier screening test result bears a nonzero residual risk (RR) for the individual to have an affected child. The RR depends on the prevalence of specific conditions and the detection rate (DR) of the test itself. Herein, we provide a detailed approach for calculating DR and RR. DR was calculated on the basis of the sum of disease allele frequencies (DAFs) of pathogenic variants found in published literature. As a proof of concept, DAF data for cystic fibrosis were compared with society guidelines. The DAF data calculated by this method were consistent with the published cystic fibrosis guideline. In addition, we compared DAF for four genes (ABCC8, ASPA, GAA, and MMUT) across three laboratories, and outlined the likely reasons for discrepancies between these laboratories. The utility of carrier screening is to support couples with information while making reproductive choices. Accurate development of DR and RR is therefore critical. The method described herein provides an unbiased and transparent process to collect, calculate, and report these data.


Asunto(s)
Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Fibrosis Quística/genética , Fibrosis Quística/prevención & control , Frecuencia de los Genes , Tamización de Portadores Genéticos/métodos , Amidohidrolasas/genética , Consanguinidad , Familia , Asesoramiento Genético/métodos , Humanos , Tamizaje Masivo/métodos , Receptores de Sulfonilureas/genética , alfa-Glucosidasas/genética
2.
Thyroid ; 29(11): 1594-1605, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31469053

RESUMEN

Background: Gene panels are routinely used to assess predisposition to hereditary cancers by simultaneously testing multiple susceptibility genes and/or variants. More recently, genetic panels have been implemented as part of solid tumor malignancy testing assessing somatic alterations. One example is targeted variant panels for thyroid nodules that are not conclusively malignant or benign upon fine-needle aspiration (FNA). We systematically reviewed published studies from 2009 to 2018 that contained genetic data from preoperative FNA specimens on cytologically indeterminate thyroid nodules (ITNs) that subsequently underwent surgical resection. Pooled prevalence estimates per gene and variant, along with their respective positive predictive values (PPVs) for malignancy, were calculated. Summary: Our systematic search identified 540 studies that were supplemented by 18 studies from bibliographies or personal files. Sixty-one studies met all inclusion criteria and included >4600 ITNs. Overall, 26% of nodules contained at least 1 variant or fusion. However, half of them did not include details on the specific gene, variant, and/or complete fusion pair reported for inclusion toward PPV calculations. The PPVs of genomic alterations reported at least 10 times were limited to BRAFV600E (98%, 95% confidence interval [CI 96-99%]), PAX8/PPARG (55% [CI 34-78%]), HRASQ61R (45% [CI 22-72%]), BRAFK601E (42% [CI 19-68%]), and NRASQ61R (38% [CI 23-55%]). Excluding BRAFV600E, the pooled PPV for all other specified variants and fusions was 47%. Multiple variants within the same nodule were identified in ∼1% of ITN and carried a cumulative PPV of 77%. Conclusions: The chance that a genomic alteration predicts malignancy depends on the individual variant or fusion detected. Only five alterations were reported at least 10 times; BRAFV600E had a PPV of 98%, while the remaining four had individual PPVs ranging from 38% to 55%. The small sample size of most variants and fusion pairs found among ITNs, however, limits confidence in their individual PPV point estimates. Better specific reporting of genomic alterations with cytological category, histological subtype, and cancer staging would facilitate better understanding of cancer prediction, and the independent contribution of the genomic profile to prognosis.


Asunto(s)
Nódulo Tiroideo/genética , Nódulo Tiroideo/patología , Análisis Mutacional de ADN , Variación Genética , Humanos , Mutación
3.
Obstet Gynecol ; 124(2 Pt 1): 210-218, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25004354

RESUMEN

OBJECTIVE: To estimate performance of a single-nucleotide polymorphism-based noninvasive prenatal screen for fetal aneuploidy in high-risk and low-risk populations on single venopuncture. METHODS: One thousand sixty-four maternal blood samples from 7 weeks of gestation and beyond were included; 1,051 were within specifications and 518 (49.3%) were low risk. Cell-free DNA was amplified, sequenced, and analyzed using the Next-generation Aneuploidy Test Using SNPs algorithm. Samples were called as trisomies 21, 18, 13, or monosomy X, or euploid, and male or female. RESULTS: Nine hundred sixty-six samples (91.9%) successfully generated a cell-free DNA result. Among these, sensitivity was 100% for trisomy 21 (58/58, confidence interval [CI] 93.8-100%), trisomy 13 (12/12, CI 73.5-100%), and fetal sex (358/358 female, CI 99.0-100%; 418/418 male, CI 99.1-100%), 96.0% for trisomy 18 (24/25, CI 79.7-99.9%), and 90% for monosomy X (9/10, CI 55.5-99.8%). Specificity for trisomies 21 and 13 was 100% (905/905, CI 99.6-100%; and 953/953, CI 99.6-100%, respectively) and for trisomy 18 and monosomy X was 99.9% (938/939, CI 99.4-100%; and 953/954, CI 99.4-100%, respectively). However, 16% (20/125) of aneuploid samples did not return a result; 50% (10/20) had a fetal fraction below the 1.5th percentile of euploid pregnancies. Aneuploidy rate was significantly higher in these samples (P<.001, odds ratio 9.2, CI 4.4-19.0). Sensitivity and specificity did not differ in low-risk and high-risk populations. CONCLUSIONS: This noninvasive prenatal screen performed with high sensitivity and specificity in high-risk and low-risk cohorts. Aneuploid samples were significantly more likely to not return a result; the number of aneuploidy samples was especially increased among samples with low fetal fraction. This underscores the importance of redraws or, in rare cases, invasive procedures based on low fetal fraction. LEVEL OF EVIDENCE: II.


Asunto(s)
Aneuploidia , Trastornos de los Cromosomas/diagnóstico , ADN/sangre , Síndrome de Down/diagnóstico , Polimorfismo de Nucleótido Simple , Diagnóstico Prenatal/métodos , Trisomía/diagnóstico , Síndrome de Turner/diagnóstico , Adolescente , Adulto , Algoritmos , Sistema Libre de Células , Cromosomas Humanos Par 13 , Cromosomas Humanos Par 18 , Femenino , Humanos , Masculino , Persona de Mediana Edad , Embarazo , Factores de Riesgo , Sensibilidad y Especificidad , Síndrome de la Trisomía 13 , Síndrome de la Trisomía 18 , Adulto Joven
4.
Reprod Biomed Online ; 21(7): 838-47, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21051290

RESUMEN

This article reports the results from a study of couples participating in a research protocol in which IVF/preimplantation genetic diagnosis (PGD) was available for non-medical sex selection. The study sought to characterize the moral attitudes and beliefs of couples actively pursuing IVF/PGD solely for purposes related to sex selection. Eighteen couples participated in ethnographic interviews from November 2005 to April 2006. These interviews explored couples' motivations for pursuing sex selection, moral beliefs and attitudes regarding sex selection and sources of moral ambivalence about the use of IVF/PGD for sex selection. Couples reported a combination of motivations for pursuing sex selection, including a desire to limit family size, concerns about parental age and financial concerns about multiple pregnancies. Many couples compared their decision to choices about abortion, maintaining that individuals have a right to make such decisions privately. Couples frequently expressed anxiety about telling their other children and family members about their plans to use IVF/PGD for sex selection. Few couples cited concerns about the physical or emotional burdens of IVF/PGD. The study's findings suggest that couples pursuing IVF/PGD for sex selection view this as an ethically complex decision and express considerable uncertainty about the ethical acceptability of this practice.


Asunto(s)
Conocimientos, Actitudes y Práctica en Salud , Principios Morales , Diagnóstico Preimplantación , Preselección del Sexo/ética , Preselección del Sexo/psicología , Adulto , Confidencialidad , Composición Familiar , Femenino , Fertilización In Vitro/economía , Fertilización In Vitro/ética , Fertilización In Vitro/psicología , Costos de la Atención en Salud , Humanos , Masculino , Motivación , Diagnóstico Preimplantación/ética , Diagnóstico Preimplantación/psicología , Derechos Sexuales y Reproductivos/ética , Derechos Sexuales y Reproductivos/psicología , Texas
5.
Genet Med ; 8(11): 719-27, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17108764

RESUMEN

PURPOSE: This study was designed to evaluate the feasibility of using a targeted array-CGH strategy for prenatal diagnosis of genomic imbalances in a clinical setting of current pregnancies. METHODS: Women undergoing prenatal diagnosis were counseled and offered array-CGH (BCM V4.0) in addition to routine chromosome analysis. Array-CGH was performed with DNA directly from amniotic fluid cells with whole genome amplification, on chorionic villus samples with amplification as necessary, and on cultured cells without amplification. RESULTS: Ninety-eight pregnancies (56 amniotic fluid and 42 CVS specimens) were studied with complete concordance between karyotype and array results, including 5 positive cases with chromosomal abnormalities. There was complete concordance of array results for direct and cultured cell analysis in 57 cases tested by both methods. In 12 cases, the array detected copy number variation requiring testing of parental samples for optimal interpretation. Array-CGH results were available in an average of 6 and 16 days for direct and cultured cells, respectively. Patient acceptance of array-CGH testing was 74%. CONCLUSION: This study demonstrates the feasibility of using array-CGH for prenatal diagnosis, including reliance on direct analysis without culturing cells. Use of array-CGH should increase the detection of abnormalities relative to the risk, and is an option for an enhanced level of screening for chromosomal abnormalities in high risk pregnancies.


Asunto(s)
Aberraciones Cromosómicas , Análisis por Micromatrices/métodos , Hibridación de Ácido Nucleico/métodos , Diagnóstico Prenatal/métodos , Bandeo Cromosómico/métodos , Cromosomas Humanos Par 3 , Toma de Decisiones , Femenino , Dosificación de Gen , Asesoramiento Genético , Humanos , Masculino , Embarazo
6.
Reprod Biomed Online ; 9(2): 225-30, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15333256

RESUMEN

Many couples are now seeking preimplantation genetic diagnosis (PGD) and fluorescence in-situ hybridization (FISH) as an alternative approach to avoid spontaneous abortion by ensuring transfer of presumed chromosomally normal embryos. This case report describes unexpected findings in a couple having three spontaneous abortions and two failed IVF cycles. In two IVF PGD cycles, four of 13 (30.8%) embryos (blastomeres) demonstrated duplication involving the Down syndrome critical region, detectable by a locus specific chromosome 21 probe. The same duplication was subsequently detected by FISH in 66 of 1002 (6.6%) sperm nuclei, demonstrating paternal gonadal mosaicism. Cytogenetic studies of peripheral blood revealed normal karyotypes in both the male and female partners. This identification of paternal germ cell or gonadal mosaicism suggests that analysis of sperm nuclei prior to undergoing IVF with PGD may be of value in patients with recurrent spontaneous abortions or multiple failed IVF.


Asunto(s)
Aborto Habitual/genética , Núcleo Celular/ultraestructura , Mosaicismo , Diagnóstico Preimplantación/métodos , Espermatozoides/ultraestructura , Adulto , Blastocisto/metabolismo , Síndrome de Down/diagnóstico , Síndrome de Down/genética , Transferencia de Embrión , Padre , Femenino , Fertilización , Fertilización In Vitro/métodos , Humanos , Hibridación Fluorescente in Situ , Cariotipificación , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA